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###### Extraction table of reviewed clinical trials.
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  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Date             Bordia et al. 1997                                                                                                                                                       Bordia et al. 1997                                                                       Janssen et al. 1996                                                                               Jiang et al. 2004                                                                                                                           Lumb. 1994                                                                     Srivastava 1989                                                                           Verma et al. 1993                                                                                                                                       Young et al. 2006
  Study design            Placebo-controlled trial                                                                                                                                                 Placebo-controlled trial                                                                 Randomised, placebo-controlled cross-over trial                                                   Randomized, open label, three-way cross-over trial                                                                                          Randomised, double-blinded placebo-controlled cross-over trial                 Open-label single-arm trial                                                               Randomised placebo-controlled trial                                                                                                                     Cross-over trial
  Sample Size             N = 60                                                                                                                                                                   N = 20                                                                                   N = 18                                                                                            N = 12                                                                                                                                      N = 8                                                                          N = 7                                                                                     N = 20                                                                                                                                                  N = 10 for each group
  Total study period:     3 months.                                                                                                                                                                One day                                                                                  6 weeks (3x2 weeks)                                                                               3x13 days, 14 days washout period between each study period.                                                                                2x1 day, at least 14 days washout period.                                      7 days                                                                                    14 days, high-calorie diet for first 7 days, high-calorie diet and ginger/placebo consumed for next 7 days.                                             72 days, 4x washout period of 7--10 days, 5x7 days intervention consumed
  Population              Patients with confirmed myocardial infarction                                                                                                                            Patients with confirmed myocardial infarction                                            Healthy volunteers                                                                                Healthy male volunteers                                                                                                                     Healthy male volunteers                                                        Health female volunteers                                                                  Health male volunteers                                                                                                                                  Healthy & Hypertensive volunteers
  Outcomes measured at:   Baseline, 1.5 months and 3 months.                                                                                                                                       Outcomes measured at: baseline, 4 hours post-consumption                                 Outcomes measured at day 12 and 14 of each study period.                                          Outcomes measured at multiple time points, starting 2 days pre-warfarin consumption to 7 days post-consumption                              Outcomes measured immediately before, 3h, and 24h post consumption of ginger   Outcomes measured at baseline and 7 days post-consumption                                 Outcomes measured at baseline, 7, and 14 days                                                                                                           Outcomes measured at baseline and 7 days post-consumption for each intervention
  Intervention            Dose: 4g per day of unstandardized capsules                                                                                                                              Dose: 10g single dose of unstandardized capsules                                         Dose: 15g raw & 40g cooked ginger placebo, once per day. Contained within 125g custard            Dose: 3.6g (3x0.4g, thrice per day) of unstandardized capsules. Consumed with 25 mg dose of rac-warfarin, consumed once per study period.   Dose: 2g (4x500mg) dried ginger per day of unstandardized capsules             Dose: 5g raw ginger per day                                                               Dose: 5g (4x625mg, twice per day) dry ginger powder of Unstandardized capsules. Consumed with 100g (2x50g) butter, 2 cups of milk, 8 slices of bread.   Dose: 1g dried ginger per day, either alone or in combination with 10mg nifedipine
  Outcome                 Platelet aggregation                                                                                                                                                     Platelet aggregation                                                                     Thromboxane B2 production (Payton Aggregation Module)                                             Platelet aggregation                                                                                                                        Platelet aggregation                                                           Platelet thromboxane B2 production                                                        Platelet aggregation                                                                                                                                    Platelet aggregation
                          \- Agonist(s): ADP and Epi                                                                                                                                               \- Agonist(s): ADP and Epi                                                                                                                                                                 \- Agonist(s): AA                                                                                                                           \- Agonist(s): AA, ADP, collagen, ristocetin                                                                                                                             \- Agonist(s): ADP and Epi                                                                                                                              \- Agonist(s): ADP, Epi, collagen
                          \- Method (Device, if reported): Turbidimetric                                                                                                                           \- Method (Device, if reported): Turbidimetric                                                                                                                                             \- Method (Device, if reported): Turbidimetric (Chrono-log)                                                                                 \- Method (Device, if reported): Electrical impedance (Chrono-log)                                                                                                       \- Method (Device, if reported): turbidimetric (ELVI-840)                                                                                               \- Method (Device, if reported): Turbidimetric (Chronolog 560)
                          Fibrinogen                                                                                                                                                                                                                                                                                                                                                          INR                                                                                                                                         Bleeding time                                                                                                                                                                                                                                                                                                                     
                          Fibrinolytic activity                                                                                                                                                                                                                                                                                                                                               Plasma warfarin enantiomer protein binding & warfarin enantiomer concentrations                                                             Platelet count                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                              Urinary S-7-hydroxywarfarin                                                                                                                 Thromboelastography                                                                                                                                                                                                                                                                                                               
  Results                 Ginger had no significant effect on both measures of aggregation                                                                                                         Reduction of both measures of platelet aggregation when compared to placebo (p\<0.05).   Both types of ginger had no significant effect on maximum thromboxane B2 production (p = 0.616)   No significant changes in any outcome                                                                                                       No significant changes in any outcome at any time point.                       Ginger consumption resulted in a 37% inhibition of thromboxane B2 production (p\<0.01).   Ginger significantly reduced platelet aggregation using both agonists when compared to placebo group (p\<0.001).                                        Ginger combined with nifedipine resulted in a significant decrease in platelet aggregation (p\<0.001). Ginger alone had no significant effect.
  Country                 India                                                                                                                                                                    India                                                                                    Netherlands                                                                                       Australia                                                                                                                                   UK                                                                             Denmark                                                                                   India                                                                                                                                                   Taiwan
  Level of evidence       III-1[\*](#t001fn002){ref-type="table-fn"}                                                                                                                               III-1                                                                                    II                                                                                                III-1                                                                                                                                       II                                                                             III-3                                                                                     II                                                                                                                                                      III-2
  Comment                 Ginger had no significant effect on blood lipids or blood sugar. Results relating to fenugreek excluded from table. No mention of randomisation. P value not reported.   This study was detailed in same manuscript as previous study.                                                                                                                              No placebo group was included in study. Results relating to ginkgo group excluded from table. P value not reported.                                                                                                        Results relating to onion group excluded from table.                                      Platelet aggregation reduced close to baseline but did not decrease further.                                                                            No placebo group. Unclear if participants were blinded.
  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AA, arachidonic acid; ADP, Adenosine Diphosphate; Epi, epinephrine; INR, International Normalised Ratio; TxB2, Thromboxane B2;.

\* Indicates some study details were missing and that scoring was based on details available.
